Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $7K fell 100.0% year over year, behind the -39.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 95.8% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -39.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 29.11M USD
- Year-over-year change
- +149.8%
- 4-year CAGR
- +17.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.11M | +149.8% |
| FY2024 | 2024-12-31 | 11.65M | -22.8% |
| FY2023 | 2023-12-31 | 15.09M | -45.7% |
| FY2022 | 2022-12-31 | 27.81M | +82.4% |
| FY2021 | 2021-12-31 | 15.25M | — |
Financing Cash Flow vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 financing cash flow of $13.61M is the 9th largest of the 11 companies compared; the peer median is $120.57M.
- Its year-over-year change of -39.4% is the 7th highest of 10, against a peer median of +85.0%.
- Over three fiscal years its annual growth of +1.5% compares with a peer median of +114.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $306.39M | +17210.3% | +114.1% | — | |
| LTM Mar 2026 | $224.57M | +85.0% | +72.0% | 452.9% | |
| LTM Mar 2026 | $212.95M | +1074.3% | +2184.5% | — | |
| LTM Jun 2026 | $179.14M | -6.5% | +434.4% | 105.4% | |
| LTM Mar 2026 | $133.79M | +14802.1% | +19.6% | — | |
| LTM Mar 2026 | $107.35M | — | +221.5% | — | |
| LTM Mar 2026 | $69.59M | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $20.66M | -94.1% | -57.0% | 9.5% | |
| LTM Mar 2026 | $13.61M | -39.4% | +1.5% | — | |
| LTM Mar 2026 | $7.94M | -98.0% | +114.7% | 36.7% | |
| LTM Mar 2026 | $95.27K | -100.2% | +17.8% | 19.1% | |
| Peer median (excluding NVCT) | $120.57M | +85.0% | +114.4% | 40.5% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.